Join
Live feed
·
INSIDERFilingvia Quantisnow
Inozyme Pharma Inc. logo

CEO & Chairman Treco Douglas A converted options into 25,000 shares and sold $7,849 worth of shares (8,819 units at $0.89), increasing direct ownership by 65% to 41,046 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
INZY· Inozyme Pharma Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INZY (Inozyme Pharma Inc.) and more on Quantisnow.

CEO & Chairman Treco Douglas A converted options into 25,000 shares and sold $7,849 worth of shares (8,819 units at $0.89), increasing direct ownership by 65% to 41,046 units (SEC Form 4) | Quantisnow